|
|
|
|
Welcome to MédiMabs !
MédiMabs is a recently established worldwide antibody, R&D and multi-service company based in Montreal, Canada. It specializes in providing research grade monoclonal antibodies, both novel and known, for which defined affinity and purity specifications exist. It offers varied opportunities such as de novo antibody generation and peptide design and synthesis. It collaborates on R&D projects, and acts as a distributor of existing antibody catalogs.
|
|
|
|
|
|
|
| LATEST NEWS |
Médimabs is proud to announce the licensing of a monoclonal antibody against HRS protein involved in trafficking and endocytosis.
Médimabs is proud to announce the licensing of five monoclonal antibodies against Staufen1 and Staufen2 involved in RNA transport.
Médimabs is proud to announce the licensing of two monoclonal antibodies against N- or C-terminal portion of T-cell Protein Tyrosine Phosphatase (TC-PTP) for immunomodulation research. |
|
|
|
|
